SEC Form 4 · accession 0001193125-26-355735
Viridian Therapeutics, Inc.\DE · VRDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Radhika Tripuraneni
Officer — Chief Medical Officer
Period of report
Aug 14, 2026
Accepted (ET)
Aug 18, 2026 · 5:34 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001590750
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 14, 2026 | M | 40,000 | $13.21 | A | 40,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $13.21 | Aug 14, 2026 | M | 40,000 | D | — | Jul 1, 2034 | Common Stock | 40,000 | 0 | D |
Explanation of responses
- F1The option is fully vested.